ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q2 Revenue: USD 53.4 K

LB filings
2025.08.14 20:33
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 53.4 K.

EPS: As of FY2025 Q2, the actual value is USD -0.43.

Segment Revenue

  • Total Revenue: $53,400 for the three months ended June 30, 2025, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, total revenue was $53,400, compared to $35,720 for the same period in 2024.

Operational Metrics

  • Net Loss: - $1,640,232 for the three months ended June 30, 2025, compared to - $8,236,368 for the same period in 2024. For the six months ended June 30, 2025, net loss was - $5,851,418, compared to - $9,514,854 for the same period in 2024.
  • Gross Margin: $17,922 for the three months ended June 30, 2025, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, gross margin was $17,922, compared to $12,502 for the same period in 2024.
  • General and Administrative Expenses: $1,171,137 for the three months ended June 30, 2025, compared to $5,977,277 for the same period in 2024. For the six months ended June 30, 2025, general and administrative expenses were $2,610,689, compared to $6,952,851 for the same period in 2024.
  • Research and Development Expenses: $479,657 for the three months ended June 30, 2025, compared to $2,252,325 for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $3,248,892, compared to $2,565,092 for the same period in 2024.
  • Interest Expense: $7,360 for the three months ended June 30, 2025, compared to $6,766 for the same period in 2024. For the six months ended June 30, 2025, interest expense was $9,759, compared to $9,413 for the same period in 2024.

Cash Flow

  • Operating Cash Flow: - $1,906,648 for the six months ended June 30, 2025, compared to - $2,322,772 for the same period in 2024.
  • Financing Activities: Generated $374,029 for the six months ended June 30, 2025, compared to $2,050,858 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue developing bioactive compounds derived from its proprietary algal culture, targeting human and animal diseases. It aims to seek strategic partners for late-stage development, regulatory preparation, and commercialization of its products in key global markets.
  • Non-Core Business: ZIVO is also focusing on producing algal biomass in Peru, which contains various nutrients and is positioned as a functional food ingredient and nutritional enhancement for human and animal use. The company has contracts for the sale and production of its algal biomass and has engaged an independent distributor to sell the product branded Zivolife®.
  • Funding Requirements: The company has noted substantial doubt about its ability to continue as a going concern and will need to secure additional funding through public or private equity or debt financings, collaborations, or partnerships to continue operations.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.